Sector: Energy
Director information for DMC GLOBAL INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| James O’Leary | Executive Chairman of the Board; Executive Chairman, President and Chief Executive Officer | 63 | ["Comprehensive leadership experience in a range of industries", "Deep experience in building and industrial products", "Diverse board experience", "Served as Chairman and Chief Executive Officer of WireCo Worldgroup, Inc.", "Served as Chairman of the Board and Chief Executive Officer of Kaydon Corporation, Inc.", "Certified public accountant (currently inactive)", "Holds a B.B.A. from Pace University", "Holds an M.B.A. from the Wharton School of Business at the University of Pennsylvania"] | [] | 2026 |
| John R. Doubman | Chief Executive Officer | ["Executive leadership and operational experience in specialty chemicals and industrial manufacturing", "Strategic planning, business development and portfolio management experience", "Technical and business background in engineering-driven industries"] | ["Risk", "Compensation"] | 2026 | |
| Michael A. Kelly | Director | ["Diversified background in finance, operations and the life sciences industry", "Extensive skills in executive leadership, finance, operations and management", "In depth experience with a multinational company operating in global markets", "More than two decades of executive experience in senior leadership roles in the life sciences industry", "Founded and served as President of Sentry Hill Partners, LLC since January 2018", "Worked at Amgen, Inc. from 2003 to 2017", "Served as Chief Financial Officer of Tanox, Inc. from 2000 to 2003", "Vice President, Finance and Corporate Controller of Biogen, Inc. from 1998 to 2000", "Vice President, Finance and Chief Financial Officer of Nutrasweet Kelco Company from 1996 to 1998", "Served on the board of directors of HOOKIPA Pharma, Inc. from February 2019 to April 2023", "Served on the board of directors of Aprea Therapeutics, Inc. from August 2020 to May 2022", "Currently serves as an independent member of the board of directors for each of Amicus Therapeutics, Inc., NeoGenomics, Inc., and Prime Medicine, Inc."] | ["Compensation (Chair)", "Corporate Governance and Nominating", "Risk"] | 2026 | |
| Ouma Sananikone | Director | ["Extensive financial and management background in investment banking and finance", "Significant experience in strategic planning at both executive and board levels", "Deep leadership experience in the finance and investment management sectors"] | ["Corporate Governance and Nominating (Chair)", "Audit"] | 2026 | |
| Ruth I. Dreessen | Director | ["Extensive financial and management background in investment banking and private equity in the chemical and related industries", "Substantial experience in financial analysis, capital markets and strategic planning", "Over two decades of financial leadership experience in the chemical, energy and petrochemical industries"] | ["Audit (Chair)", "Compensation", "Corporate Governance and Nominating"] | 2026 | |
| Sharon S. Spurlin | Director | ["Extensive financial leadership experience in the energy, midstream and petrochemical industries", "Significant expertise in corporate finance, governance and risk management", "Public company board and audit committee leadership experience"] | ["Audit", "Risk"] | 2026 |
